Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma
Open Access
- 1 January 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 6 (1), 138-146
- https://doi.org/10.1158/1535-7163.mct-06-0436
Abstract
Hepatocellular carcinoma (HCC) is a common malignancy in Asia and Africa. We previously reported that overexpression of extracellular signal-regulated kinase (ERK) kinase 1/2 (MEK1/2) and ERK1/2 was detected in HCC, and that their activation was required for liver cancer cell proliferation and survival. In the present study, we determined the efficacy of a specific MEK1/2 inhibitor AZD6244 (ARRAY-142886) in treatment of HCC. Treatment of primary HCC cells with AZD6244 led to growth inhibition, elevation of the cleavage of caspase-3 and caspase-7, and cleaved poly(ADP)ribose polymerase, but inhibition of ERK1/2 and p90RSK phosphorylation. Studying the protein expression profile of seven HCC xenografts revealed that their growth rate was positively correlated with the levels of phosphorylated MEK. AZD6244, when given p.o. to mice bearing these xenografts, resulted in a dose-dependent inhibition of tumor growth. AZD6244-induced growth suppression was associated with inactivation of ERK1/2 and p90RSK, and up-regulation of activated caspase-3 and caspase-7, and cleaved poly(ADP)ribose polymerase. Our data suggest that the MEK-ERK pathway plays an important role in the growth and survival of liver cancer cells and that the HCC xenograft models are excellent tools for screening preclinical drugs. Targeted inhibition of the MEK-ERK pathway with AZD6244 may represent an alternative approach for the treatment of this disease. [Mol Cancer Ther 2007;6(1):138–45]Keywords
This publication has 38 references indexed in Scilit:
- Xenografts of Human Hepatocellular Carcinoma: A Useful Model for Testing DrugsClinical Cancer Research, 2006
- Molecular cloning and characterization of a novel gene which is highly expressed in hepatocellular carcinomaOncogene, 2002
- Phosphorylation of MEK1 by cdk5/p35 Down-regulates the Mitogen-activated Protein Kinase PathwayPublished by Elsevier BV ,2002
- Neoadjuvant and adjuvant therapy for operable hepatocellular carcinomaPublished by Wiley ,1999
- Myosin Light Chain Kinase Functions Downstream of Ras/ERK to Promote Migration of Urokinase-type Plasminogen Activator-stimulated Cells in an Integrin-selective MannerThe Journal of cell biology, 1999
- Proteases to die forGenes & Development, 1998
- Integrin αvβ3 Requirement for Sustained Mitogen-activated Protein Kinase Activity during AngiogenesisThe Journal of cell biology, 1998
- An Induced Proximity Model for Caspase-8 ActivationJournal of Biological Chemistry, 1998
- PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in VivoJournal of Biological Chemistry, 1995
- Hepatocellular carcinomaJournal of Hepatology, 1992